Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-13
2008-05-13
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S342000, C514S370000, C548S195000, C548S205000, C548S190000, C546S269700
Reexamination Certificate
active
07371770
ABSTRACT:
Compounds of formula (I) as defined herein:inhibit the formation of the β-amyloid peptide (β-A4) and are, therefore, useful in the treatment of pathologies in which a β-amyloid peptide (β-A4) formation inhibitor provides a therapeutic benefit. Particular such pathologies are senile dementia, Alzheimer's disease, Down's syndrome, Parkinson's disease, amyloid angiopathy, cerebrovascular disorders, frontotemporal dementias and Pick's disease, post-traumatic dementias, pathologies linked to neuroinflammatory processes, Huntington's disease and Korsakov's syndrome.
REFERENCES:
patent: 2004/0152747 (2004-08-01), Chen et al.
patent: WO 03/014095 (2003-02-01), None
patent: WO 2004/009565 (2004-01-01), None
patent: WO 2004/033439 (2004-04-01), None
Baltzer Sylvie
Dorsselaer Viviane Van
Pascal Marc
Anderson Rebecca
Chu Yong
Newman Irving
Sanofi-aventis
LandOfFree
Acylaminothiazole derivatives and use thereof as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylaminothiazole derivatives and use thereof as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylaminothiazole derivatives and use thereof as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813878